Vyripharm Biopharmaceuticals today announced the hiring of Dr. David Yang as Vice President of Research and Development to the Company. In this role, Dr. Yang will aid the Company in working on various aspects of drug development and drug delivery system technologies as well as Vyripharm’s theranostic imaging platforms currently in development.
Vyripharm Biopharmaceuticals is pleased to announce a research agreement with MD Anderson Cancer Center, the world’s No. 1 cancer center, to study the effects of medicinal cannabinoids on cancer therapy.
Vyripharm is a biopharmaceutical firm focused on natural products, regulatory testing, pharmaceutical drug development, data storage, monitoring technology, development of imaging agents, and drug delivery systems. The aim of Vyripharm is to improve clinical management through diagnosis and treatment with, botanicals, synthetic pharmaceuticals, and drug delivery systems.
While marijuana is currently prohibited in Texas, it is only a matter of time before medical and recreational use is legalized, as the last Viewpoint series produced by the Baker Institute Drug Policy Program argued. When this happens, it will make the cannabis industry open for business in Texas. As we can see from the experiences of states that have legalized recreational and/or medical cannabis, the industry has strong potential for growth. It also faces significant challenges. The future direction for the marijuana industry is important to consider for entrepreneurs, investors, policymakers and the public. In this Baker Institute Viewpoints series, which runs through Friday, five experts on the marijuana industry examine the question, “What does the future hold for the cannabis industry, in Texas and beyond?” The third commentary follows. Previous entries covered growing pains and challenges in Texas.